Fibrocell Science Inc (FCSC) Stock Rating Upgraded by Zacks Investment Research
Fibrocell Science Inc (NASDAQ:FCSC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
A number of other analysts also recently commented on FCSC. ValuEngine downgraded shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. HC Wainwright reiterated a “buy” rating and issued a $5.70 price objective on shares of Fibrocell Science in a report on Friday, June 9th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $7.00 price objective (up previously from $3.00) on shares of Fibrocell Science in a report on Monday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $4.74.
Fibrocell Science (NASDAQ FCSC) traded up 5.96% on Friday, reaching $3.38. The company had a trading volume of 114,100 shares. Fibrocell Science has a 1-year low of $1.57 and a 1-year high of $4.64. The company’s 50-day moving average price is $2.92 and its 200 day moving average price is $2.60. The firm’s market capitalization is $49.74 million.
Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.31) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.31). Fibrocell Science had a negative net margin of 4,307.60% and a negative return on equity of 293.07%. On average, equities analysts forecast that Fibrocell Science will post ($2.17) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Fibrocell Science Inc (FCSC) Stock Rating Upgraded by Zacks Investment Research” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/15/fibrocell-science-inc-fcsc-stock-rating-upgraded-by-zacks-investment-research.html.
A hedge fund recently raised its stake in Fibrocell Science stock. Creative Planning grew its position in Fibrocell Science Inc (NASDAQ:FCSC) by 395.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,090 shares of the company’s stock after buying an additional 48,755 shares during the period. Creative Planning owned 0.42% of Fibrocell Science worth $245,000 as of its most recent SEC filing. 54.70% of the stock is owned by institutional investors and hedge funds.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.